An observational study in Coronary Artery Disease, sponsored by JW Medical Systems Ltd. Recruiting at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.
Sponsored by JW Medical Systems Ltd (part of Blue Sail Medical Co., Ltd.) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Coronary Artery Disease by Blue Sail Medical Co., Ltd. — 8 open to participants now, 11 under way, none of them phase 3. Coronary Artery Disease · Blue Sail Medical Co., Ltd..
Among the 23 studies in Coronary Artery Disease by Blue Sail Medical Co., Ltd., this one is one of 5 that started in 2024, is one of 7 observational ones, reaches primary completion later than 5 of the 10 other live ones, and was the 19th registered.
4,865 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →8 of the 23 studies in Coronary Artery Disease by Blue Sail Medical Co., Ltd. are open now, in 2 countries. Recruiting first, the newest first:
Biosensors Europe SA · Sites in Malaysia
Ages 18+
Shanghai Bluesail Boyuan Medical Technology Co., Ltd. · Sites in China
Ages 18–80
Shanghai Bluesail Boyuan Medical Technology Co., Ltd. · Sites in China
Ages 18+
Shanghai Bluesail Boyuan Medical Technology Co., Ltd. · Sites in China
Ages 18–80
JW Medical Systems Ltd
Ages 18–80
By country, each count listing its studies:
Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 5 started in 2024.
This study's planned enrollment of 400 is above the median of 323 across 1,690 observational studies indexed under Coronary Artery Disease.
Median enrollment 200 across the 16 interventional studies, 1,121 across the 7 observational. Of the 8 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under JW Medical Systems Ltd, one of the names counted as Blue Sail Medical Co., Ltd.. Under that name alone:
JW Medical Systems Ltd is the lead sponsor of 13 studies on the registry; 5 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 23 studies in Coronary Artery Disease by Blue Sail Medical Co., Ltd., from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study was to further evaluate the long-term safety and efficacy of the Biolimus Coated Coronary Artery Balloon Dilation Catheter in the real world.
The study population was patients with primary coronary vascular lesions with a blood vessel diameter of 2.0mm-2.75mm.
Study Design:
Recruit 300 subjects in China and a total of 100 subjects in Indonesia and Thailand who meet the criteria for study inclusion to use at least one Biolimus coated coronary balloon dilation catheter (BioAscend) to treat primary in situ coronary artery vascular disease with a diameter of 2.0mm-2.75mm regardless of the number of blood vessels, the length and number of treated lesions;
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Use at least one Biolimus coated coronary balloon dilation catheter (BioAscend) to treat primary in situ coronary artery vascular disease with a diameter of 2.0 mm-2.75 mm regardless of the number of blood vessels, the length and number of treated lesions.
Device: Biolimus Coated Coronary Artery Balloon Dilation Catheter
Patients with Coronary Artery Disease will be treated with Biolimus Coated Coronary Artery Balloon Dilation Catheter
Target lesion failure rate (TLF)
Target lesion failure rate (TLF) at 12 months after surgery, including cardiogenic death, target vascular myocardial infarction, and clinically symptom-driven target lesion revascularization (CD-TLR)
Time frame: 12 months after surgery
Interventional success rate
Including device success rate, pathogenic power and clinical success rate
Time frame: Immediately after operation
Device-related cardiovascular clinical composite endpoint
Device-related cardiovascular clinical composite endpoints from postoperative to pre-discharge, day 30, month 6, month 12, and month 24, including cardiac death, target vessel myocardial infarction, and clinically symptom-driven target lesion revascularization (excluding elective interventional therapy)Device-related cardiovascular clinical composite endpoints from postoperative to pre-discharge, day 30, month 6, month 12, and month 24, including cardiac death, target vessel myocardial infarction, and clinically symptom-driven target lesion revascularization (excluding elective interventional therapy)
Time frame: From postoperative to before discharge, day 30, month 6, month 12, month 24
Patient-related cardiovascular clinical composite endpoint
Patient-related cardiovascular clinical composite endpoints including all-cause mortality, all myocardial infarction, and any revascularization (excluding elective interventional therapy) from postoperative to pre-discharge, day 30, month 6, month 12, and month 24
Time frame: From postoperative to before discharge, day 30, month 6, month 12, month 24
Major adverse cardiac events (MACEs)
Including cardiac death, myocardial infarction, and target lesion revascularization (TLR) at postoperative to pre-discharge, day 30, month 6, month 12, and month 24.
Time frame: From postoperative to before discharge, day 30, month 6, month 12, month 24
Incidence of thrombotic events as defined by ARC
Including identified, probable, and unexcluded thrombosis in the acute, subacute, and late periods acute, subacute, and late Defined, probable, and non-excluded thrombosis within the segment
Time frame: From postoperative to before discharge, day 30, month 6, month 12, month 24
Plan to share: No
No publications or documents are linked to this record.
Ran from May 2024 to primary completion in Dec 2025, 19 months.
Of 125 industry-sponsored observational studies under Coronary Artery Disease, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 40. This study's 19 months is below that.
Counting every sponsor, half of 762 studies reached it within 41 months; a quarter within 21 and three quarters within 87.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.